# Pacific Biosciences (PACB) — Earnings

PACB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pacb/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.14 |
| EPS estimate | −$0.14 |
| EPS surprise | −2.41% |
| Revenue surprise | −0.50% |
| Revenue | $39.0M |
| Revenue estimate | $39.2M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1299130/000129913026000122/pacb-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/8bb7964c-efd3-bf4b-1f91-87c495aac0c1.html) |

Pacific Biosciences reported Q2 2026 results on August 5, 2026. The company posted a loss of $0.14 per share, matching the $0.14 estimate but listed as a 2.41% miss. Revenue of $39.0 million came in 0.50% below the $39.2 million consensus. Compared with Q2 2025, the loss was unchanged at $0.14, and revenue slipped 2% from $39.8 million.

Losses dominate the table. Only two of the last 20 quarters were profitable: Q3 2021 at $0.08 and Q4 2024 at $0.01. Full-year losses were $1.40 per share in 2022, $1.21 in 2023, $1.14 in 2024 and $1.84 in 2025. The 2025 total includes a $1.44 loss in Q1 2025, the largest in the table, while the other three quarters of 2025 were losses of $0.13 to $0.14. Annual revenue peaked here at $200.6 million in 2023, fell about 23% to $154.0 million in 2024 and reached $160.0 million in 2025. Pacific Biosciences beat the EPS estimate in 10 of the last 20 quarters.

Q3 results came between October 30 and November 7 in the past five years. That points to early November 2026 for the next report. It will show whether quarterly losses stay near the recent range.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.14 | −$0.14 | -2.41% | $39.2M | $39.0M |
| Q1 2026 | May 7, 2026 | −$0.14 | −$0.03 | 78.83% | $39.9M | $37.2M |
| Q4 2025 | Feb 12, 2026 | −$0.14 | −$0.13 | 9.53% | $43.0M | $44.6M |
| Q3 2025 | Nov 5, 2025 | −$0.15 | −$0.13 | 14.02% | $40.1M | $38.4M |
| Q2 2025 | Aug 7, 2025 | −$0.17 | −$0.14 | 18.98% | $36.6M | $39.8M |
| Q1 2025 | May 8, 2025 | −$0.19 | −$1.44 | -652.35% | $35.4M | $37.2M |
| Q4 2024 | Feb 13, 2025 | −$0.19 | $0.01 | 105.19% | $40.1M | $39.2M |
| Q3 2024 | Nov 7, 2024 | −$0.22 | −$0.22 | 0.32% | $41.9M | $40.0M |
| Q2 2024 | Aug 7, 2024 | −$0.23 | −$0.64 | -174.68% | $40.9M | $36.0M |
| Q1 2024 | May 9, 2024 | −$0.28 | −$0.29 | -5.26% | $43.4M | $38.8M |
| Q4 2023 | Feb 15, 2024 | −$0.29 | −$0.31 | -8.05% | $57.5M | $58.4M |
| Q3 2023 | Oct 30, 2023 | −$0.29 | −$0.26 | 10.13% | $48.8M | $55.7M |
| Q2 2023 | Aug 2, 2023 | −$0.32 | −$0.28 | 12.50% | $40.2M | $47.6M |
| Q1 2023 | May 2, 2023 | −$0.33 | −$0.36 | -8.50% | $34.4M | $38.9M |
| Q4 2022 | Feb 16, 2023 | −$0.36 | −$0.37 | -2.69% | $26.2M | $27.4M |
| Q3 2022 | Nov 7, 2022 | −$0.33 | −$0.34 | -2.50% | $35.4M | $32.3M |
| Q2 2022 | Aug 3, 2022 | −$0.34 | −$0.32 | 5.41% | $35.2M | $35.5M |
| Q1 2022 | May 4, 2022 | −$0.32 | −$0.37 | -15.59% | $32.9M | $33.2M |
| Q4 2021 | Feb 15, 2022 | −$0.28 | −$0.31 | -9.42% | $36.1M | $36.0M |
| Q3 2021 | Nov 2, 2021 | −$0.22 | $0.08 | 136.04% | $33.6M | $34.9M |

## Frequently Asked Questions

### When did Pacific Biosciences (PACB) last report earnings?

Pacific Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did PACB beat earnings estimates?

No. Pacific Biosciences reported EPS of −$0.14 for Q2 2026 against a −$0.14 estimate — a 2.41% miss.

### How much revenue did PACB report last quarter?

Pacific Biosciences reported $39.0M in revenue for Q2 2026, against a consensus estimate of $39.2M.

## Similar Stocks

- [TXG](https://www.lighthorse.io/tickers/txg) — 10x Genomics, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).